Cross-talk between bradykinin and epidermal growth factor in regulating IL-6 production in human airway smooth muscle cells

Po Hao Feng, Te Chih Hsiung, Han Pin Kuo, Chien Da Huang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Bradykinin (BK), a G-protein-coupled-receptor (GPCR) agonist via the B2 receptor induces interleukin (IL)-6 expression in airway smooth muscle (ASM) cells by involving the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway. In some cell species, GPCR agonists have been shown to activate the ERK 1/2 pathway via transactivation of epidermal growth factor (EGF) receptor (EGFR). In this study, we tested whether there is cross-talk between BK and EGF in the regulation of IL-6 gene expression in ASM cells. Methods: ASM cells were treated with BK, EGF, AG-1478 and genistein. IL-6 production was analyzed by enzyme-linked immunosorbent assay (ELISA). Immunoblot study was used for detection of ERK1/2 activation. Transactivation of EGFR phosphorylation was detected by immunoprecipitation. Results: ELISA showed that EGF (10 ng/ml, 18 hr) increased IL-6 secretion (from 234 ± 35 to 923 ± 494 pg/ml, n = 5, p > 0.05), and significantly enhanced BK-induced IL-6 secretion (from 4383 ± 296 to 8312 ± 1267 pg/ml, n = 5, p <0.05) in ASM. Moreover, AG-1478 (2 μM), reduced BK-induced IL-6 secretion by 28% and abrogated the synergic induction of IL-6 induced by BK plus EGF (from 8312 ± 1267 to 3229 ± 597 pg/ml, n = 5, p <0.05). AG-1478 dual effects on IL-6 secretion induced by BK alone or BK plus EGF were also observed in cells treated with genistein, a tyrosine kinase inhibitor, and AG-825, an ErbB-2 inhibitor. Immunoblot analysis demonstrated that AG-1478 had no effect on ERK1/2 activation by BK (1 μM, 10 min). Immunoprecipitation studies showed that BK (1 μM for 2, 5 and 10 min) did not directly transactivate EGFR phosphorylation. Conclusion: These data show that BK and EGF act in concert to regulate the expression of IL-6 in ASM cells possibly via transcriptional mechanisms involving EGFR-associated key signaling molecules.

Original languageEnglish
Pages (from-to)92-99
Number of pages8
JournalChang Gung Medical Journal
Volume33
Issue number1
Publication statusPublished - Jan 2010
Externally publishedYes

Fingerprint

Bradykinin
Epidermal Growth Factor
Smooth Muscle Myocytes
Interleukin-6
Epidermal Growth Factor Receptor
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Genistein
G-Protein-Coupled Receptors
Immunoprecipitation
Transcriptional Activation
Enzyme-Linked Immunosorbent Assay
Phosphorylation
Interleukin-6 Receptors
Protein-Tyrosine Kinases
Smooth Muscle
Gene Expression

Keywords

  • Airway smooth muscle
  • Bradykinin
  • EGF
  • EGF receptor
  • IL-6

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cross-talk between bradykinin and epidermal growth factor in regulating IL-6 production in human airway smooth muscle cells. / Feng, Po Hao; Hsiung, Te Chih; Kuo, Han Pin; Huang, Chien Da.

In: Chang Gung Medical Journal, Vol. 33, No. 1, 01.2010, p. 92-99.

Research output: Contribution to journalArticle

@article{7f91307a58be4d1eae44d089266dc7ec,
title = "Cross-talk between bradykinin and epidermal growth factor in regulating IL-6 production in human airway smooth muscle cells",
abstract = "Background: Bradykinin (BK), a G-protein-coupled-receptor (GPCR) agonist via the B2 receptor induces interleukin (IL)-6 expression in airway smooth muscle (ASM) cells by involving the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway. In some cell species, GPCR agonists have been shown to activate the ERK 1/2 pathway via transactivation of epidermal growth factor (EGF) receptor (EGFR). In this study, we tested whether there is cross-talk between BK and EGF in the regulation of IL-6 gene expression in ASM cells. Methods: ASM cells were treated with BK, EGF, AG-1478 and genistein. IL-6 production was analyzed by enzyme-linked immunosorbent assay (ELISA). Immunoblot study was used for detection of ERK1/2 activation. Transactivation of EGFR phosphorylation was detected by immunoprecipitation. Results: ELISA showed that EGF (10 ng/ml, 18 hr) increased IL-6 secretion (from 234 ± 35 to 923 ± 494 pg/ml, n = 5, p > 0.05), and significantly enhanced BK-induced IL-6 secretion (from 4383 ± 296 to 8312 ± 1267 pg/ml, n = 5, p <0.05) in ASM. Moreover, AG-1478 (2 μM), reduced BK-induced IL-6 secretion by 28{\%} and abrogated the synergic induction of IL-6 induced by BK plus EGF (from 8312 ± 1267 to 3229 ± 597 pg/ml, n = 5, p <0.05). AG-1478 dual effects on IL-6 secretion induced by BK alone or BK plus EGF were also observed in cells treated with genistein, a tyrosine kinase inhibitor, and AG-825, an ErbB-2 inhibitor. Immunoblot analysis demonstrated that AG-1478 had no effect on ERK1/2 activation by BK (1 μM, 10 min). Immunoprecipitation studies showed that BK (1 μM for 2, 5 and 10 min) did not directly transactivate EGFR phosphorylation. Conclusion: These data show that BK and EGF act in concert to regulate the expression of IL-6 in ASM cells possibly via transcriptional mechanisms involving EGFR-associated key signaling molecules.",
keywords = "Airway smooth muscle, Bradykinin, EGF, EGF receptor, IL-6",
author = "Feng, {Po Hao} and Hsiung, {Te Chih} and Kuo, {Han Pin} and Huang, {Chien Da}",
year = "2010",
month = "1",
language = "English",
volume = "33",
pages = "92--99",
journal = "Chang Gung Medical Journal",
issn = "0255-8270",
publisher = "Chang Gung Medical Journal",
number = "1",

}

TY - JOUR

T1 - Cross-talk between bradykinin and epidermal growth factor in regulating IL-6 production in human airway smooth muscle cells

AU - Feng, Po Hao

AU - Hsiung, Te Chih

AU - Kuo, Han Pin

AU - Huang, Chien Da

PY - 2010/1

Y1 - 2010/1

N2 - Background: Bradykinin (BK), a G-protein-coupled-receptor (GPCR) agonist via the B2 receptor induces interleukin (IL)-6 expression in airway smooth muscle (ASM) cells by involving the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway. In some cell species, GPCR agonists have been shown to activate the ERK 1/2 pathway via transactivation of epidermal growth factor (EGF) receptor (EGFR). In this study, we tested whether there is cross-talk between BK and EGF in the regulation of IL-6 gene expression in ASM cells. Methods: ASM cells were treated with BK, EGF, AG-1478 and genistein. IL-6 production was analyzed by enzyme-linked immunosorbent assay (ELISA). Immunoblot study was used for detection of ERK1/2 activation. Transactivation of EGFR phosphorylation was detected by immunoprecipitation. Results: ELISA showed that EGF (10 ng/ml, 18 hr) increased IL-6 secretion (from 234 ± 35 to 923 ± 494 pg/ml, n = 5, p > 0.05), and significantly enhanced BK-induced IL-6 secretion (from 4383 ± 296 to 8312 ± 1267 pg/ml, n = 5, p <0.05) in ASM. Moreover, AG-1478 (2 μM), reduced BK-induced IL-6 secretion by 28% and abrogated the synergic induction of IL-6 induced by BK plus EGF (from 8312 ± 1267 to 3229 ± 597 pg/ml, n = 5, p <0.05). AG-1478 dual effects on IL-6 secretion induced by BK alone or BK plus EGF were also observed in cells treated with genistein, a tyrosine kinase inhibitor, and AG-825, an ErbB-2 inhibitor. Immunoblot analysis demonstrated that AG-1478 had no effect on ERK1/2 activation by BK (1 μM, 10 min). Immunoprecipitation studies showed that BK (1 μM for 2, 5 and 10 min) did not directly transactivate EGFR phosphorylation. Conclusion: These data show that BK and EGF act in concert to regulate the expression of IL-6 in ASM cells possibly via transcriptional mechanisms involving EGFR-associated key signaling molecules.

AB - Background: Bradykinin (BK), a G-protein-coupled-receptor (GPCR) agonist via the B2 receptor induces interleukin (IL)-6 expression in airway smooth muscle (ASM) cells by involving the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway. In some cell species, GPCR agonists have been shown to activate the ERK 1/2 pathway via transactivation of epidermal growth factor (EGF) receptor (EGFR). In this study, we tested whether there is cross-talk between BK and EGF in the regulation of IL-6 gene expression in ASM cells. Methods: ASM cells were treated with BK, EGF, AG-1478 and genistein. IL-6 production was analyzed by enzyme-linked immunosorbent assay (ELISA). Immunoblot study was used for detection of ERK1/2 activation. Transactivation of EGFR phosphorylation was detected by immunoprecipitation. Results: ELISA showed that EGF (10 ng/ml, 18 hr) increased IL-6 secretion (from 234 ± 35 to 923 ± 494 pg/ml, n = 5, p > 0.05), and significantly enhanced BK-induced IL-6 secretion (from 4383 ± 296 to 8312 ± 1267 pg/ml, n = 5, p <0.05) in ASM. Moreover, AG-1478 (2 μM), reduced BK-induced IL-6 secretion by 28% and abrogated the synergic induction of IL-6 induced by BK plus EGF (from 8312 ± 1267 to 3229 ± 597 pg/ml, n = 5, p <0.05). AG-1478 dual effects on IL-6 secretion induced by BK alone or BK plus EGF were also observed in cells treated with genistein, a tyrosine kinase inhibitor, and AG-825, an ErbB-2 inhibitor. Immunoblot analysis demonstrated that AG-1478 had no effect on ERK1/2 activation by BK (1 μM, 10 min). Immunoprecipitation studies showed that BK (1 μM for 2, 5 and 10 min) did not directly transactivate EGFR phosphorylation. Conclusion: These data show that BK and EGF act in concert to regulate the expression of IL-6 in ASM cells possibly via transcriptional mechanisms involving EGFR-associated key signaling molecules.

KW - Airway smooth muscle

KW - Bradykinin

KW - EGF

KW - EGF receptor

KW - IL-6

UR - http://www.scopus.com/inward/record.url?scp=77649221516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649221516&partnerID=8YFLogxK

M3 - Article

C2 - 20184800

AN - SCOPUS:77649221516

VL - 33

SP - 92

EP - 99

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

SN - 0255-8270

IS - 1

ER -